MX2019004940A - Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. - Google Patents

Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.

Info

Publication number
MX2019004940A
MX2019004940A MX2019004940A MX2019004940A MX2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A MX 2019004940 A MX2019004940 A MX 2019004940A
Authority
MX
Mexico
Prior art keywords
dkk
antibody
beta
cancer
catenin
Prior art date
Application number
MX2019004940A
Other languages
English (en)
Inventor
H Kagey Michael
A Sirard Cynthia
Original Assignee
Leap Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leap Therapeutics Inc filed Critical Leap Therapeutics Inc
Publication of MX2019004940A publication Critical patent/MX2019004940A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

La presente solicitud describe un método para tratar un cáncer en un sujeto que lo necesite. El cáncer puede ser un cáncer esofágico, un cáncer uterino, un cáncer de hígado o un colangiocarcinoma. El método comprende administrar al sujeto una cantidad efectiva de un anticuerpo anti-Dkk-1 o un fragmento de unión a antígeno del mismo, en el que se determina que el sujeto tiene una mutación de activación constitutiva de la proteína beta-catenina.
MX2019004940A 2016-10-26 2017-10-26 Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. MX2019004940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413198P 2016-10-26 2016-10-26
PCT/US2017/058555 WO2018081437A1 (en) 2016-10-26 2017-10-26 Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Publications (1)

Publication Number Publication Date
MX2019004940A true MX2019004940A (es) 2019-09-26

Family

ID=60570180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004940A MX2019004940A (es) 2016-10-26 2017-10-26 Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.

Country Status (14)

Country Link
US (2) US11267876B2 (es)
EP (1) EP3532099A1 (es)
JP (2) JP7374765B2 (es)
KR (1) KR20190085935A (es)
CN (1) CN110114087A (es)
AU (1) AU2017347822A1 (es)
BR (1) BR112019008279A2 (es)
CA (1) CA3041325A1 (es)
IL (1) IL266199A (es)
MA (1) MA46673A (es)
MX (1) MX2019004940A (es)
RU (1) RU2019115946A (es)
SG (1) SG11201903602RA (es)
WO (1) WO2018081437A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019115946A (ru) 2016-10-26 2020-11-27 Лип Терапьютикс, Инк. Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1
AU2020216494A1 (en) * 2019-02-01 2021-08-12 Board Of Regents, The University Of Texas System Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof
WO2021055789A1 (en) * 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
JP2023502666A (ja) * 2019-11-22 2023-01-25 リープ セラピューティクス，インコーポレイテッド Ｄｋｋ－１阻害剤を用いて癌を処置する方法
WO2023183940A2 (en) * 2022-03-24 2023-09-28 The Translational Genomics Research Institute Peptide inhibitors targeting the tbl1-beta-catenin complex

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2008097510A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Antibodies specific for dkk-1
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
ES2703208T3 (es) 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
CA2931975A1 (en) * 2013-12-02 2015-06-11 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
RU2019115946A (ru) 2016-10-26 2020-11-27 Лип Терапьютикс, Инк. Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1

Also Published As

Publication number Publication date
CN110114087A (zh) 2019-08-09
JP2023133432A (ja) 2023-09-22
JP2019533693A (ja) 2019-11-21
AU2017347822A1 (en) 2019-05-09
US20190284264A1 (en) 2019-09-19
MA46673A (fr) 2019-09-04
US11267876B2 (en) 2022-03-08
IL266199A (en) 2019-06-30
RU2019115946A (ru) 2020-11-27
JP7374765B2 (ja) 2023-11-07
BR112019008279A2 (pt) 2019-07-09
EP3532099A1 (en) 2019-09-04
KR20190085935A (ko) 2019-07-19
US20220289831A1 (en) 2022-09-15
CA3041325A1 (en) 2018-05-03
RU2019115946A3 (es) 2021-01-26
WO2018081437A1 (en) 2018-05-03
SG11201903602RA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2019004940A (es) Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MY195110A (en) Antibodies to PD-1 and uses Thereof
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
WO2016144728A3 (en) Anti-lilrb antibodies and their use in detecting and treating cancer
NZ631197A (en) Anti sez6 antibodies and methods of use
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
AR099465A1 (es) Anticuerpos anti-jagged1 y métodos de uso
EP3370707A4 (en) METHOD FOR THE TREATMENT OF CANCER, USING COMPOSITIONS OF ANTIBODIES AND CARRIER PROTEINS WITH ANTIBODY PRESERVATION
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
NZ628314A (en) Cd47 antibodies and methods of use thereof
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2021000439A (es) Anticuerpos de antigeno anti-tf humanizado.